The UK government has started ordering COVID-19 vaccines for a 2022 booster campaign, including a 32 million-dose order for the Pfizer/BioNTech shot, even before third doses for 2021 have b
Private equity group Carlyle has said it won't raise its offer for respiratory drug specialist Vectura to match a 165p per share offer from tobacco giant Philip Morris International (PMI).<
Europe's market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according
AstraZeneca's Forxiga has become the first SGLT2 inhibitor to be approved in Europe for use in people with chronic kidney disease, extending its lead over rival drugs in the class.
A flurry of new offers by Philip Morris International (PMI) and private equity firm Carlyle has hiked the value of respiratory medicines company Vectura to £1 more than a billion ($1.4 bill
Moderna made a massive $4.2 billion from sales of just under 200 million doses of its COVID-19 vaccine, taking its tally since approval to around $6 billion from 302 million shots.